Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 USD | -0.21% | +3.30% | +68.46% |
May. 01 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
Financials (USD)
Sales 2024 * | 2.03M | Sales 2025 * | - | Capitalization | 25.14M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | - | EV / Sales 2024 * | 12.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.15
x | P/E ratio 2025 * |
-
| Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.09% |
1 day | -0.21% | ||
1 week | +3.30% | ||
Current month | +1.73% | ||
1 month | -5.43% | ||
3 months | +19.29% | ||
6 months | +82.17% | ||
Current year | +68.46% |
Managers | Title | Age | Since |
---|---|---|---|
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
Anthony DelConte
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Krista Fogarty
AUD | Comptroller/Controller/Auditor | 56 | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Dana Ono
BRD | Director/Board Member | 71 | 14-01-05 |
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
John W. Higuchi
BRD | Director/Board Member | 56 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 4.7 | -0.21% | 25,742 |
24-05-01 | 4.71 | +1.95% | 9,055 |
24-04-30 | 4.62 | -2.33% | 28,681 |
24-04-29 | 4.73 | -1.41% | 28,711 |
24-04-26 | 4.798 | +5.44% | 19,754 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.46% | 25.14M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- LPCN Stock